Reversal effects of antifungal drugs on multidrug resistance in MDR1-overexpressing HeLa cells

被引:36
作者
Iida, N
Takara, K
Ohmoto, N
Nakamura, T
Kimura, T
Wada, A
Hirai, M
Sakaeda, T
Okumura, K
机构
[1] Kobe Univ, Sch Med, Dept Hosp Pharm, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Kyoto Pharmaceut Univ, Fac Pharmaceut Sci, Dept Hosp Pharm, Yamashima Ku, Kyoto 6078414, Japan
[3] Kobe Pharmaceut Univ, Dept Clin Pharm, Higashinada Ku, Kobe, Hyogo 6588558, Japan
关键词
MDR1; itraconazole; reversal of MDR;
D O I
10.1248/bpb.24.1032
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
In this study, the antiproliferative effects of vinblastine (VLB), paclitaxel (TXL), doxorubicin (DXR), daunorubicin (DNR) and 5-fluorouracil (5-FU) were assessed in the human cervical carcinoma cell line HeLa-Ohio (HeLa) and Hvr100-6 cells, established by growing the parental HeLa cells in the presence of progressively greater concentrations of VLB in the culture medium. Flow cytometric analysis indicated the induction of MDR1 (P-glycoprotein) in Hvr100-6 cells with no alterations in levels of multidrug resistance-associated protein (MRP). Resistance to VLB, TXL, DXR and DNR was found in Hvr100-6 cells with relative resistances of ca. 300, 4000, 50 and 200, respectively, whereas no resistance was found to 5-FU. The reversal effects of antifungal drugs, fluconazole, itraconazole, ketoconazole, miconazole and amphotericin B on multidrug resistance were also assessed using Hvr100-6 cells. Itraconazole was found to have potent reversal effect on the resistance to VLB and TXL, but the others had no such effect. This reversal effect of itraconazole was concentration-dependent, with dose modifying factors of 3.2, 10.1 and 435.7 at 0.1, 0.25 and 0.5 mum of itraconazole, respectively. In addition, this reversal effect of itraconazole was explained by the inhibition of accumulation of the anticancer drugs.
引用
收藏
页码:1032 / 1036
页数:5
相关论文
共 24 条
[1]
COMPARATIVE EFFECTS OF THE ANTIMYCOTIC DRUGS KETOCONAZOLE, FLUCONAZOLE, ITRACONAZOLE AND TERBINAFINE ON THE METABOLISM OF CYCLOSPORINE BY HUMAN LIVER-MICROSOMES [J].
BACK, DJ ;
TJIA, JF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (05) :624-626
[2]
Clinical pharmacokinetics ol fluconazole in superficial and systemic mycoses [J].
Debruyne, D .
CLINICAL PHARMACOKINETICS, 1997, 33 (01) :52-77
[3]
FLENS MJ, 1994, CANCER RES, V54, P4557
[4]
REVERSAL OF DAUNORUBICIN RESISTANCE IN P388/ADR CELLS BY ITRACONAZOLE [J].
GUPTA, S ;
KIM, JM ;
GOLLAPUDI, S .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (04) :1467-1469
[5]
FUNCTIONAL-ROLE FOR THE 170-KDA TO 180-KDA GLYCOPROTEIN SPECIFIC TO DRUG-RESISTANT TUMOR-CELLS AS REVEALED BY MONOCLONAL-ANTIBODIES [J].
HAMADA, H ;
TSURUO, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (20) :7785-7789
[6]
IKEZAKI K, 1984, CANCER RES, V44, P1791
[7]
Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: Comparison with the effects on CYP3A4 [J].
Katoh, M ;
Nakajima, M ;
Yamazaki, H ;
Yokoi, T .
PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1189-1197
[8]
Kim RB, 1999, PHARMACEUT RES, V16, P408
[9]
Kurosawa M, 1996, ANN HEMATOL, V72, P17
[10]
POTENTIATION OF 5-FLUOROURACIL, CHROMOMYCIN A3, AND BLEOMYCIN BY AMPHOTERICIN-B OR POLYMYXIN-B IN TRANSFORMED FIBROBLASTIC CELLS [J].
KUWANO, M ;
KAMIYA, T ;
ENDO, H ;
KOMIYAMA, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1973, 3 (05) :580-584